S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
3 Stocks Set to Lead the Nasdaq Bull Market
WARNING: Do You Invest with these Banks (Ad)pixel
Stocks end higher on Wall Street; economic worries hit oil
Myanmar executions revive pressure for more sanctions
Is Ford About To Crush Workhorse Group? 
WARNING: Do You Invest with these Banks (Ad)pixel
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
3 Stocks Set to Lead the Nasdaq Bull Market
WARNING: Do You Invest with these Banks (Ad)pixel
Stocks end higher on Wall Street; economic worries hit oil
Myanmar executions revive pressure for more sanctions
Is Ford About To Crush Workhorse Group? 
WARNING: Do You Invest with these Banks (Ad)pixel
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
3 Stocks Set to Lead the Nasdaq Bull Market
WARNING: Do You Invest with these Banks (Ad)pixel
Stocks end higher on Wall Street; economic worries hit oil
Myanmar executions revive pressure for more sanctions
Is Ford About To Crush Workhorse Group? 
WARNING: Do You Invest with these Banks (Ad)pixel
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
3 Stocks Set to Lead the Nasdaq Bull Market
WARNING: Do You Invest with these Banks (Ad)pixel
Stocks end higher on Wall Street; economic worries hit oil
Myanmar executions revive pressure for more sanctions
Is Ford About To Crush Workhorse Group? 
WARNING: Do You Invest with these Banks (Ad)pixel
NASDAQ:CORT

Corcept Therapeutics - CORT Stock Forecast, Price & News

$28.07
-0.34 (-1.20%)
(As of 08/15/2022 12:00 AM ET)
Add
Compare
Today's Range
$27.92
$28.39
50-Day Range
$20.39
$29.12
52-Week Range
$15.82
$29.93
Volume
515,487 shs
Average Volume
639,781 shs
Market Capitalization
$3.01 billion
P/E Ratio
29.86
Dividend Yield
N/A
Price Target
$32.00

Corcept Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
14.0% Upside
$32.00 Price Target
Short Interest
Bearish
19.03% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.43
Upright™ Environmental Score
News Sentiment
0.21mentions of Corcept Therapeutics in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$9.90 M Sold Last Quarter
Proj. Earnings Growth
18.18%
From $0.88 to $1.04 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.27 out of 5 stars

Medical Sector

451st out of 1,125 stocks

Pharmaceutical Preparations Industry

223rd out of 554 stocks

CORT stock logo

About Corcept Therapeutics (NASDAQ:CORT) Stock

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. StockNews.com cut Corcept Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday, August 5th. Truist Financial lowered Corcept Therapeutics to a "hold" rating in a research report on Tuesday, August 9th. HC Wainwright raised their price objective on Corcept Therapeutics from $29.00 to $33.00 and gave the company a "buy" rating in a research report on Thursday, August 4th. Finally, Jefferies Financial Group raised Corcept Therapeutics from a "hold" rating to a "buy" rating and raised their price objective for the company from $21.00 to $35.00 in a research report on Wednesday, July 27th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $32.00.

Corcept Therapeutics Price Performance

CORT Stock traded down $0.34 on Monday, reaching $28.07. 515,487 shares of the company traded hands, compared to its average volume of 857,244. The company has a market cap of $3.01 billion, a P/E ratio of 30.22, a price-to-earnings-growth ratio of 2.86 and a beta of 0.51. The firm has a fifty day simple moving average of $25.43 and a 200-day simple moving average of $23.25. Corcept Therapeutics has a one year low of $15.82 and a one year high of $29.93.

Insiders Place Their Bets

In other Corcept Therapeutics news, insider Sean Maduck sold 25,000 shares of Corcept Therapeutics stock in a transaction on Monday, July 18th. The stock was sold at an average price of $27.37, for a total value of $684,250.00. Following the completion of the sale, the insider now owns 40,024 shares of the company's stock, valued at approximately $1,095,456.88. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Corcept Therapeutics news, insider Sean Maduck sold 25,000 shares of Corcept Therapeutics stock in a transaction on Monday, July 18th. The stock was sold at an average price of $27.37, for a total value of $684,250.00. Following the completion of the sale, the insider now owns 40,024 shares of the company's stock, valued at approximately $1,095,456.88. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Gary Charles Robb sold 45,000 shares of Corcept Therapeutics stock in a transaction on Wednesday, July 6th. The stock was sold at an average price of $26.00, for a total value of $1,170,000.00. Following the completion of the sale, the insider now directly owns 24,123 shares of the company's stock, valued at approximately $627,198. The disclosure for this sale can be found here. In the last quarter, insiders sold 384,980 shares of company stock valued at $9,895,043. Corporate insiders own 18.60% of the company's stock.

Receive CORT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corcept Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CORT Stock News Headlines

Corcept Therapeutics (NASDAQ:CORT) Downgraded by StockNews.com
Corcept Therapeutics (CORT) Q2 Earnings Lag Estimates
Corcept Therapeutics - Drug Development
CORT Crosses Above Average Analyst Target
See More Headlines
Receive CORT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corcept Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CORT Company Calendar

Last Earnings
11/03/2021
Today
8/15/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:CORT
CUSIP
21835210
Employees
238
Year Founded
1998

Price Target and Rating

Average Stock Price Forecast
$32.00
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$30.00
Forecasted Upside/Downside
+14.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$112.51 million
Pretax Margin
33.66%

Debt

Sales & Book Value

Annual Sales
$365.98 million
Cash Flow
$0.99 per share
Book Value
$3.26 per share

Miscellaneous

Free Float
87,183,000
Market Cap
$3.01 billion
Optionable
Optionable
Beta
0.51

Social Links















CORT Stock - Frequently Asked Questions

Should I buy or sell Corcept Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Corcept Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CORT shares.
View CORT analyst ratings
or view top-rated stocks.

What is Corcept Therapeutics' stock price forecast for 2022?

4 Wall Street research analysts have issued 1-year price objectives for Corcept Therapeutics' stock. Their CORT share price forecasts range from $30.00 to $35.00. On average, they predict the company's stock price to reach $32.00 in the next year. This suggests a possible upside of 14.0% from the stock's current price.
View analysts price targets for CORT
or view top-rated stocks among Wall Street analysts.

How have CORT shares performed in 2022?

Corcept Therapeutics' stock was trading at $19.80 at the start of the year. Since then, CORT stock has increased by 41.8% and is now trading at $28.07.
View the best growth stocks for 2022 here
.

When is Corcept Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our CORT earnings forecast
.

How were Corcept Therapeutics' earnings last quarter?

Corcept Therapeutics Incorporated (NASDAQ:CORT) posted its quarterly earnings data on Wednesday, November, 3rd. The biotechnology company reported $0.24 EPS for the quarter, topping the consensus estimate of $0.19 by $0.05. The biotechnology company had revenue of $96.13 million for the quarter, compared to analyst estimates of $97.75 million. Corcept Therapeutics had a net margin of 28.75% and a trailing twelve-month return on equity of 25.53%. During the same period in the previous year, the business posted $0.17 earnings per share.

What guidance has Corcept Therapeutics issued on next quarter's earnings?

Corcept Therapeutics issued an update on its FY 2022 earnings guidance on Wednesday, August, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $400.00 million-$430.00 million, compared to the consensus revenue estimate of $414.43 million.

What is Joseph K. Belanoff's approval rating as Corcept Therapeutics' CEO?

6 employees have rated Corcept Therapeutics Chief Executive Officer Joseph K. Belanoff on Glassdoor.com. Joseph K. Belanoff has an approval rating of 100% among the company's employees. This puts Joseph K. Belanoff in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Corcept Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corcept Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), CA (CA), Alibaba Group (BABA), BlackRock (BLK), Inovio Pharmaceuticals (INO), Pfizer (PFE) and Activision Blizzard (ATVI).

What is Corcept Therapeutics' stock symbol?

Corcept Therapeutics trades on the NASDAQ under the ticker symbol "CORT."

Who are Corcept Therapeutics' major shareholders?

Corcept Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (7.31%), Parallel Advisors LLC (2.56%), Boston Trust Walden Corp (1.23%), Northern Trust Corp (0.93%), Principal Financial Group Inc. (0.61%) and S&T Bank PA (0.47%). Insiders that own company stock include Daniel N Swisher Jr, G Leonard Baker Jr, G Leonard Baker, Jr, Gary Charles Robb, Joseph Douglas Lyon, Joseph K Belanoff and Sean Maduck.
View institutional ownership trends
.

How do I buy shares of Corcept Therapeutics?

Shares of CORT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Corcept Therapeutics' stock price today?

One share of CORT stock can currently be purchased for approximately $28.07.

How much money does Corcept Therapeutics make?

Corcept Therapeutics (NASDAQ:CORT) has a market capitalization of $3.01 billion and generates $365.98 million in revenue each year. The biotechnology company earns $112.51 million in net income (profit) each year or $0.94 on an earnings per share basis.

How many employees does Corcept Therapeutics have?

The company employs 238 workers across the globe.

When was Corcept Therapeutics founded?

Corcept Therapeutics was founded in 1998.

How can I contact Corcept Therapeutics?

Corcept Therapeutics' mailing address is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. The official website for the company is www.corcept.com. The biotechnology company can be reached via phone at (650) 327-3270, via email at cjames@corcept.com, or via fax at 650-327-3218.

This page (NASDAQ:CORT) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.